What the latest science tells us, the latest on ADHD

Understanding ADHD in 2025: What the Latest Science Reveals

Over the past decade, our understanding of Attention Deficit Hyperactivity Disorder (ADHD) has changed dramatically. Once viewed largely as a childhood behavioural issue, ADHD is now recognised as a complex, lifelong neurodevelopmental condition affecting people of all ages — and new research in 2024–2025 is reshaping how we approach diagnosis and treatment here in the UK. From groundbreaking genetic discoveries to new perspectives on adult ADHD and emotional regulation, the science is painting a fuller, more compassionate picture of this often-misunderstood condition.

1. ADHD: A Lifelong Condition, Not Just for Kids

One of the most significant developments in recent years has been the widespread acknowledgement that ADHD often persists into adulthood. A major UK cohort study conducted by King’s College London as part of the Dunedin Multidisciplinary Health and Development Research Unit followed individuals from childhood into mid-life. Their 2024 publication showed that around 70% of those diagnosed in childhood continued to meet diagnostic criteria for ADHD at age 25 and beyond (Source: APA PsycNet, 2024).

This aligns with NHS data showing a sharp rise in adult referrals, particularly among women. Historically, ADHD was underdiagnosed in females due to gender-biased diagnostic criteria that focused on hyperactivity — a symptom more commonly seen in boys. This has left generations of women undiagnosed and struggling with the cognitive and emotional toll of untreated ADHD.

2. The Genetics of ADHD: A Heritable Condition Comes into Focus

While ADHD has long been known to run in families, the specific genetic factors have only recently come to light. In 2024, researchers from the Psychiatric Genomics Consortium, including UK partners at Cardiff University, published findings identifying 27 new genetic loci associated with ADHD in the largest genome-wide association study (GWAS) to date (Source: Nature Genetics, 2024).

These genes are linked to neurotransmitter regulation and brain development, particularly in areas responsible for attention, planning, and impulse control. While we're not at the stage of genetic testing for ADHD, this research confirms that biology — not poor parenting or personal failure — plays a central role in the condition.

3. Neuroimaging Studies Confirm ADHD as a Brain-Based Condition

Advanced brain imaging has allowed researchers to compare the brain structures and functions of people with and without ADHD. Recent studies from UCL’s Institute of Cognitive Neuroscience have revealed structural and functional differences in regions like the prefrontal cortex, cerebellum, and the default mode network (DMN) — the part of the brain associated with mind-wandering and internal thoughts.

These findings were reinforced by a meta-analysis in Neuroscience & Biobehavioral Reviews (2025), which showed that individuals with ADHD tend to have reduced cortical thickness and altered connectivity in executive function networks (Source: NBR, 2025).

This helps explain why people with ADHD often struggle with organisation, time management, and task-switching. Crucially, it dismantles the long-standing stigma that ADHD is a “behavioural problem” rather than a neurological one.

4. Emotional Dysregulation Now Seen as a Core Symptom

One of the most overlooked — yet debilitating — aspects of ADHD is emotional dysregulation. While not listed as a core symptom in the DSM-5 or ICD-11, recent UK and European research has called for its inclusion, especially in adult cases.

A 2024 study from the University of Southampton highlighted how traits like rejection-sensitive dysphoria, emotional reactivity, and difficulty with mood regulation are prevalent in over 80% of adults with ADHD, often leading to misdiagnoses of anxiety, depression, or personality disorders (Source: Journal of Affective Disorders, 2024).

This has major implications for diagnosis and treatment. If emotional symptoms are more accurately recognised as part of ADHD, individuals can receive more appropriate care — including therapy and medication that address emotional regulation, not just attention and impulsivity.

5. CBT and Lifestyle Interventions Offer Hope Beyond Medication

Stimulant medications like methylphenidate (Ritalin) and lisdexamfetamine (Elvanse) remain the frontline treatment for ADHD, and the evidence for their effectiveness is robust. However, there's growing interest in non-pharmacological treatments.

A 2025 NHS-backed trial across five UK mental health trusts tested CBT programs tailored specifically for adults with ADHD. Participants showed statistically significant improvements in emotional regulation, executive function, and quality of life — even among those already taking medication (Source: British Journal of Psychiatry, 2025).

Other lifestyle factors are also gaining attention. Recent studies have shown strong links between sleep quality and symptom severity. For instance, research from the University of Surrey found that improving sleep hygiene reduced ADHD symptoms by 25% in adult participants. Diet and physical activity, especially aerobic exercise, have also been shown to boost dopamine and executive function — further supporting a holistic approach to care.

Why This Matters in the UK?

In the UK, demand for ADHD services is growing at an unprecedented rate. NHS waiting times for assessments can exceed 18 months, and private clinics are experiencing a sharp uptick in adult referrals.

The shift in public awareness, combined with these new scientific insights, is driving a more nuanced understanding of ADHD. It’s no longer just about distracted schoolchildren — it’s about recognising and supporting a diverse population across the lifespan.

At NeuroAssess, we are proud to integrate the latest research into our operating model. Our approach blends evidence-based assessment tools, remote clinical interviews, and compassionate care to provide adults and children with the answers they deserve — without the wait.

Conclusion: A New Era for ADHD

The science is clear: ADHD is a complex, multifaceted condition with roots in biology, not bad behaviour. It affects adults just as much as children, and it demands a personalised, science-backed response.

As understanding grows, so too must our services. Whether you’re seeking a diagnosis, exploring treatment options, or supporting someone you love, staying informed is the first step.

And in 2025, there’s more reason than ever to feel hopeful.

Need Support?

If you're experiencing symptoms of ADHD and want to explore your options, our team at NeuroAssess is here to help. Learn more about our assessment services,